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Background and purpose: Hypomyelinating leukodystrophies are a heteroge-
neous group of genetic disorders with a wide spectrum of phenotypes and a
high rate of genetically unsolved cases. Bi-allelic mutations in NKX6-2 were
recently linked to spastic ataxia 8 with hypomyelinating leukodystrophy.
Methods: Using a combination of homozygosity mapping, exome sequencing,
and detailed clinical and neuroimaging assessment a series of new NKX6-2
mutations in a multicentre setting is described. Then, all reported NKX6-2
mutations and those identiﬁed in this study were combined and an in-depth
analysis of NKX6-2-related disease spectrum was provided.
Results: Eleven new cases from eight families of diﬀerent ethnic backgrounds
carrying compound heterozygous and homozygous pathogenic variants in
NKX6-2 were identiﬁed, evidencing a high NKX6-2 mutation burden in the
hypomyelinating leukodystrophy disease spectrum. Our data reveal a pheno-
type spectrum with neonatal onset, global psychomotor delay and worse prog-
nosis at the severe end and a childhood onset with mainly motor phenotype at
the milder end. The phenotypic and neuroimaging expression in NKX6-2 is
described and it is shown that phenotypes with epilepsy in the absence of overt
hypomyelination and diﬀuse hypomyelination without seizures can occur.
Conclusions: NKX6-2 mutations should be considered in patients with autoso-
mal recessive, very early onset of nystagmus, cerebellar ataxia with hypotonia
that rapidly progresses to spasticity, particularly when associated with neu-
roimaging signs of hypomyelination. Therefore, it is recommended that
O R I G I N A L A R T I C L E
Correspondence: V. Chelban, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK (tel.: +44 20 34484249; fax: +44 20
7278 5616; e-mail: v.chelban@ucl.ac.uk); N. Kaya, King Faisal Specialist Hospital and Research Centre, PO Box 3354, Riyadh 11211, Saudi
Arabia (tel.: +966 1464727239612; fax: +966 4427858; e-mail: nkaya@kfshrc.edu.sa).
*Equal contributions.
†Equal contributions.
© 2019 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology 1
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
E
U
R
O
P
E
A
N
J
O
U
R
N
A
L
O
F
N
E
U
R
O
L
O
G
Y
NXK6-2 should be included in hypomyelinating leukodystrophy and spastic
ataxia diagnostic panels.
Introduction
Hypomyelinating leukodystrophies are a heterogeneous
group of genetic disorders with a wide spectrum of phe-
notypes. Given that myelination is a highly regulated
process these disorders usually result from genetic abnor-
malities. However, the majority of individuals with
hypomyelinating disorders have no genetic diagnosis [1].
Hypomyelination can result from dysfunctions in mye-
lin generation or maintenance pathways including muta-
tions in the myelin proteins (PLP1), protein translation
(POLR3A, POLR3B, POLR1C) and gap junction pro-
teins linking astrocytes and oligodendrocytes (GJC2).
A new phenotype associated with bi-allelic muta-
tions in NKX6-2 leading to spastic ataxia 8 (SPAX8),
autosomal recessive, with hypomyelinating leukodys-
trophy (OMIM: 617560) has recently been
described by our group [2]. The reported NKX6-2
mutations were bi-allelic truncating or located in the
highly conserved homeobox domain. Clinically, they
presented with early onset spastic ataxia or hypotonia
progressing to severe spasticity within a few months
and were associated with hypomyelination [2].
Here, a large, ethnically diverse cohort is presented,
describing comprehensively an expanding clinical and
neuroimaging syndrome and a large genotypic spec-
trum of NKX6-2-related disease.
Methods
The study included aﬀected individuals with spastic ataxia
and hypomyelination from unrelated families of diﬀerent
ethnic backgrounds. Families were recruited under Insti-
tutional Review Board/ethics-approved research proto-
cols (UCLH: 04/N034) with informed consent. For
comprehensive genotype–phenotype analyses, all reported
genetically diagnosed NKX6-2 mutations were included.
Extended methods are given in Appendix S1.
Results
Genotype spectrum in NKX6-2-related disease
In this study, 11 new cases from eight families (Fig. 1)
carrying pathogenic variants in NKX6-2 were identi-
ﬁed. Eight distinct mutations were found including
four novel variants (Fig. 2a). One was present in gno-
mAD with very low allele frequency in the heterozy-
gous state (MAF 0.0001170) but absent as
homozygous (c.541C>G) (Fig. 2b), and three were
known pathogenic variants. The c.196delC identiﬁed
in families IV and V was present in a shared homozy-
gous region (Fig. 2c). All missense variants were
located in conserved amino acid positions (Fig. 2d).
Our analysis was extended to include 33 individuals
from 21 families carrying NKX6-2 mutations identiﬁed
in this study and previously reported [2–5] (Table 1,
Appendices S2 and S3). So far, 13 distinct NKX6-2
variants have been linked to SPAX8 disease. Several
mutations (c.121A>T, c.487C>G, c.196delC) were
reported in multiple families. The c.196delC and
c.487C>G were identiﬁed in ﬁve families each, all origi-
nally from the Middle East. Haplotype analysis from
three families conﬁrmed that c.196delC was a founder
mutation. However, the c.487C>G carriers did not
share the same haplotype, the mutation arising recur-
rently [5]. The c.121A>T was identiﬁed in three families
of Indian origin. Haplotype analysis data from two of
these families conﬁrmed a founder eﬀect [2].
With one exception (p.Arg101Ser), all missense
mutations aﬀected the homeobox domain. To estab-
lish the deleterious eﬀect of p.Arg101Ser variant,
reverse transcription polymerase chain reaction (RT-
PCR) and western blot were performed. Control
RT-PCR for glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) conﬁrmed the presence of cDNA in
all samples. In the patient, NKX6-2 cDNA was
severely reduced compared to controls (Fig. 3a).
Immunoblot analysis conﬁrmed a signiﬁcant reduction
in NKX6-2 protein levels in the patient compared to
controls (Fig. 3b, c, Appendix S4).
The majority of reported cases (81.8%, 27/33) pre-
sented in the ﬁrst year of life, half of these (14/27) as
neonates. Whether the mutation type inﬂuenced the
age of onset was analysed. Sixteen cases carried two
truncating alleles, 13 had bi-allelic missense mutations
and four had compound heterozygous variants includ-
ing one truncating mutation. Although an earlier
mean onset age was observed in the group harbouring
two truncating alleles versus the group with two mis-
sense alleles (7.3 months vs. 8.3 months), the diﬀer-
ence was not statistically signiﬁcant (P = 0.78).
Phenotype spectrum in NKX6-2-related disease
Assessment of the age of onset and disease severity
revealed two ends of an expanding phenotype spec-
trum of NKX6-2 mutations.
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Neonatal and very early onset
Neonatal onset was associated with a higher rate of
severe global psychomotor disability compared with
onset after 1 month of age (P = 0.05) (Fig. 4a).
Twenty cases with information on motor milestones
showed very severe motor deﬁcit, all children failing
to achieve independent ambulation and 70% (14/20)
failing to achieve head control. Furthermore, 90% of
children with disease onset before 1 year never
achieved verbal milestones/meaningful speech.
Complex medical needs included severe dysphagia
requiring gastrostomy (6/33 cases), congenital heart
disease (1/33), respiratory failure (2/33) leading to
death, undescended testicles (1/33), severe dental and/
or gum abnormalities (6/33 cases) and inguinal hernia
(1/33). Survival in this group was shorter with 12.1%
(4/33) of children dying in their ﬁrst 5 years of life.
Childhood onset
Childhood onset with predominantly motor delay and
complex spastic ataxia was identiﬁed in seven individu-
als in this study and those previously reported [2]. Case
F1-III:1 has the least severe motor phenotype in our ser-
ies (Appendix S5). Case F8-II:1 has a phenotype resem-
bling the previously reported cases with the c.121A>T
mutation – severe spastic ataxia but relatively preserved
cognition [2]. The seven cases all achieved ambulation,
although they required walking aids (walking frame) 1–
3 years into the disease and wheelchair 3–8 years later.
Features including head titubation and severe dystonia
in the previously reported patients who achieved adult-
hood suggest that they may be related to disease pro-
gression rather than genotype.
Complex spastic ataxia and developmental delay
The most common symptom at onset was nystagmus
(25/33 cases) (Fig. 4b) described as horizontal gaze-
evoked in the majority of cases. Other ocular manifes-
tations were square wave jerks, hypometric saccades,
impaired smooth pursuit and reduced visual acuities
(four cases). Limitation of bilateral, lateral gaze eye
movements was seen later in three cases who reached
adulthood.
Spasticity with brisk reﬂexes in the upper and lower
limbs and upgoing plantar responses were present in
all cases. Axial hypotonia was reported at presenta-
tion in nine patients, all with onset of disease before
1 year of age associated with upper and lower limb
spasticity soon after presentation. Cervical and/or
limb dystonia was present in around 40% of cases
where information was available. Examination of the
peripheral nervous system was normal in all cases and
normal nerve conduction studies were reported in two
cases who reached adulthood.
Seizures were present in four (12.5%) patients har-
bouring NKX6-2 mutations. Case F1-III:1 presented
primary tonic progressing to secondarily generalized
seizure at 6 years. Electroencephalography at the age
of 13 showed loss of age-based background activity
and absent anterior–posterior gradient of background
activity with focal tonic seizure presenting clinically as
hemifacial seizures. There were intermittent frequency
slowing (most pronounced at frontal electrodes), mul-
tifocal epileptic discharges (sharp waves and sharp-
slow waves) pronounced over the right hemisphere,
and several focal tonic seizures. The seizures were
multidrug-resistant. No details regarding seizure
Figure 1 Family trees in all new families reported in this study. het, heterozygous; hom, homozygous; the individuals tested in this
study are indicated with a dot.
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phenomenology are available in the other three cases
[3,5].
Cognitive function varied greatly between patients.
Interestingly, two cases reported here (F1-III:1 and
F8-II:1) and four previously reported [2] (total 6/33)
had normal cognitive development for their age. Case
F8-II:1 and the four previously reported cases with
normal cognitive development carry the homozygous
nonsense mutation p.Lys41* whilst F1-III:1 carries
two missense compound heterozygous variants
(p.Arg101Ser, p.Leu181Val). However, severe cogni-
tive impairment with arrested speech development was
present in 66% of all children with bi-allelic NKX6-2
pathogenic variants and in all reported children with
neonatal onset. It is acknowledged that, in most cases,
an accurate cognitive function assessment was diﬃcult
due to severe motor impairment and/or developmental
language delay.
Other features present in SPAX8 patients included
strabismus (4/33 patients), scoliosis (6/33), neck or/
and limb dystonia (9/33), contractures (4/33 patients),
dysmorphism (2/33), hip dislocation (2/33) and single
cases of hearing impairment and hirsutism.
Neuroimaging spectrum in NKX6-2-related disease
The key neuroimaging feature in the majority of cases
was a hypomyelinating leukodystrophy. Magnetic res-
onance imaging (MRI) (Appendix S6) showed signal
abnormality with atrophy noted supratentorially
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Figure 2 Mutation spectrum of NKX6-2-related disease. (a) NKX6-2 gene with all the mutations identiﬁed. All known and novel muta-
tions identiﬁed in our cohort are labelled with a blue star; all mutations previously reported are labelled with a magenta star and plot-
ted on top of the gene. (b) Sanger sequencing conﬁrmation with segregation analysis for novel NKX6-2 variants reported in this study.
(c) Homozygosity mapping in family IV and V identiﬁed a homozygous region on chromosome 10, shared by aﬀected individuals and
containing the pathogenic homozygous variant c.196delC in NKX6-2. (d) Conservation across species of each novel missense mutation
reported in this study.
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within the thalami and the globus pallidi. Infratentori-
ally, there was notable involvement of the pons with
signal abnormality involving the transverse pontine
ﬁbres with relative expansion to the entire pons. This
contrasted with the orthogonal oriented ﬁbres of the
corticospinal tracts of relatively normal signal, provid-
ing a distinctive prominent appearance of the mid-
pons on the axial T2-weighted sequences. Further-
more, signal change was noted in the cerebellar hemi-
spheres, particularly involving the subcortical white
matter (WM) and the dentate nuclei. Cerebellar vol-
ume was relatively increased in very young patients,
probably related to the underlying WM changes, and
demonstrated mild atrophic change over time. Not all
children developed cerebellar atrophy (Appendix S7).
Interestingly, in case F1-III:1 with two missense
compound heterozygous mutations neuroimaging ﬁnd-
ings were milder compared to cases carrying homozy-
gous truncation mutations (Fig. 4c). Marked
cerebellar atrophy was a key ﬁnding in this case. Fur-
thermore, two other paediatric NKX6-2-related cases
were reported previously without overt hypomyelina-
tion [4]. Thinning of the corpus callosum was present
in 6/33 patients. A longitudinal MRI study in F7-II:3
at 4 and 8 years old shows progressive thinning of the
corpus callosum and cerebellar atrophy, associated
with WM abnormality sparing the U ﬁbres (Fig. 4d).
Discussion
Recently the ﬁrst cases of NKX6-2 mutations leading
to the hypomyelination and spastic ataxia phenotype in
humans were described [2]. Given the rarity of
hypomyelinating disorders and the absence of an unbi-
ased cohort to screen, it is diﬃcult to estimate the fre-
quency of NKX6-2 mutations. However, genetic
analysis of the University College London (UCL)
leukodystrophies cohort identiﬁed 10 cases of
hypomyelination with pathogenic mutations in PLP1
(four families) and single cases of TUBB4A, POLR3A/
B and CLCN2 [6]. Here are presented six additional
cases (three families) of hypomyelination due to
NKX6-2 mutations from the same research group sug-
gesting a signiﬁcant burden of NKX6-2 mutations.
In this study, the phenotypic spectrum was
expanded and it was shown that NKX6-2 mutations
lead to a neonatal onset at the severe end and child-
hood onset at the milder end. Interestingly, the com-
pound heterozygous missense variants c.301C>A
(p.Arg101Ser) and c.541C>G (p.Leu181Val) led to a
signiﬁcant reduction (>70%) of the NKX6-2 protein.
It is possible that the small amount of NKX6-2 pro-
tein identiﬁed by western blot provided a degree of
myelination leading to a less severe clinical picture.
This individual and the three cases previously pub-
lished [5] presented with multidrug-resistant epilepsy.
In focal cortical dysplasia, a common cause of drug-
resistant epilepsy, hypomyelination abnormality was
conﬁrmed in numerous histopathological epilepsy sur-
gery specimen studies [7]. Focal dysplasia is currently
linked to abnormalities in the diﬀerentiation of glial
cells from their progenitors and their migration to the
cortical place [8], a process regulated by transcription
factors including NKX6-2 [9].
Additional clinical features associated with NKX6-2
mutations – cervical and/or limb dystonia, congenital
abnormalities (congenital heart disease, undescended
testes), severe dental and/or gum abnormalities –
reﬂect the developmental role of NKX6-2 as a member
of the homeobox gene family [10]. These genes are
involved in development, specifying geographical ori-
entation of the body by directing the formation of
limbs and organs [11]. Some homeobox genes such as
PAX6 [12], OTX2 [13] and MEOX1 [14] are involved
in a variety of developmental and neurological disor-
ders with brain abnormalities.
Figure 3 Functional analyses and pathogenicity of variants identiﬁed in family 1. (a) Reverse transcription polymerase chain reaction
in compound heterozygous missense case F1-III:1 showed absent or severely reduced NKX6-2 compared to control; glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was used as a loading control. (b) Reduced NKX6-2 protein levels conﬁrmed by western blot in
individual F1-III:1. Total protein lysate extracted from human ﬁbroblasts assessed by sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis and analysed by western blotting using anti-NKX6-2 antibody (left panel). (c) Densitometry analysis shows signiﬁcant
reduction in NKX6-2 protein levels in ﬁbroblasts harbouring the NKX6-2 missense mutation compared to control cells. ***P < 0.01,
replicate values, mean and SD are shown; one-way ANOVA with Bonferroni post hoc test.
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Clinical and neuroimaging ﬁndings in NKX6-2-re-
lated disease reﬂect the involvement of WM and pyra-
midal tracts (spasticity, brisk reﬂexes, upgoing
plantars), cerebellum (truncal and limb ataxia, nystag-
mus) and bulbar function (dysarthria, dysphagia).
Complications related to these clinical manifestations
led to signiﬁcant impairment in vital functions includ-
ing swallowing (although dysphagia was not routinely
assessed in all cases, severe dysphagia requiring gas-
trostomy was reported in several cases), respiration
and functionally disabling spasticity, similarly to other
myelin-related diseases [15]. Early screening and
recognition of these disease-related complications are
important aspects during the clinical assessments of
these patients.
Furthermore, our study expands the MRI spectrum
of NKX6-2 mutations from diﬀuse hypomyelination
to focal T2-weighted hyperintensity and parenchymal
volume loss. Recently, other hypomyelinating
leukodystrophy genes such as TUBB4A and POLR3A
have been shown to have distinct phenotypes and neu-
roimaging spectrum, ranging from spastic paraplegia
to spastic ataxia without overt hypomyelination to
hypomyelinating leukodystrophies resulting from dif-
ferent mutations [16,17]. A similar pattern was identi-
ﬁed in NKX6-2 with cases presenting clinically with
(a) (c)
(d)(b)
Figure 4 Genetype–phenotype correlation and neuroimaging spectrum of NKX6-2 mutations. (a) The neonatal-onset group has a sta-
tistically signiﬁcant higher frequency of global psychomotor developmental delay (red) compared with the other two groups (onset
from 2 months to 1 year and onset after 1 year). Childhood onset is associated with predominantly motor delay (blue). P = 0.05,
r2 = 0.9. (b) Clinical features associated with NKX6-2 mutations (the horizontal axis) with the number of cases on the vertical axis
(total n = 33). hor, horizontal gaze-evoked nystagmus. (c) Fluid-attenuated inversion recovery and T2-weighted MRI acquisitions
from case F1-III:1 exhibiting T2 hyperintense signal change in periventricular WM surrounding the frontal horn of the right lateral
ventricle, and frontal and temporal opercular and subinsular WM T2-weighted hyperintense signal change associated with a degree of
cortical volume loss. Note the normal signal intensity of the globi pallidi, thalami and external capsules, mesencephalon and pons.
There is disproportionate cerebellar volume loss with mild T2-weighted hyperintense signal change in the peri-dentate WM. (d) Longi-
tudinal MRI in case F7-II:3 at ages of 4 years (D1, D2) and 8½ years (D3, D4) (D1, D3, mid-sagittal T1-weighted; D2, D4, coronal
T2-weighted) showing progressive thinning of the corpus callosum and cerebellar atrophy associated with WM abnormality sparing
the U ﬁbres (2, 4). There is progressive enlargement of the cortical sulci and extra axial cerebrospinal ﬂuid spaces indicating underlying
global brain atrophy.
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spastic ataxia in the absence of hypomyelination and
a reduction of NKX6-2 protein levels (case F1-III:1)
compared to extended hypomyelination in cases with
truncating mutations resulting in no expression of
NKX6-2 protein, as previously reported [2]. There-
fore, the importance of molecular diagnosis with addi-
tional functional work and conﬁrmatory evidence is
highlighted.
In conclusion, it is shown that the phenotypic and
neuroimaging expression in NKX6-2 mutations can
range from a complex, neonatal onset at the severe
end and a childhood onset at the milder end of the
spectrum and that phenotypes with epilepsy in the
absence of overt hypomyelination, and diﬀuse
hypomyelination without seizures, can occur. It is rec-
ommended that NXK6-2 should be included in
hypomyelinating leukodystrophy and spastic ataxia
diagnostic panels.
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II:1, F6-II:6, F2-II:1). Normal to hyperintense T1
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sponding to the T2-weighted hyperintense signal (col-
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demonstrates diﬀuse T2-weighted hyperintense signal
change in subcortical, deep WM including external
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demonstrate dorsal mesencephalic and diﬀuse pontine
T2-weighted hyperintense signal change. Column 5
demonstrates diﬀuse cerebellar WM T2-weighted
hyperintense signal change including the peri-dentate
WM with relative preservation of cerebellar volume.
Appendix S7. Neuroimaging spectrum of NKX6-2-re-
lated disease.
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